Remarkable progress toward new treatments for cystic fibrosis

Lancet Respir Med. 2014 Dec;2(12):962-4. doi: 10.1016/S2213-2600(14)70272-3. Epub 2014 Nov 19.

Authors

Laurie C Eldredge¹, Bonnie W Ramsey²

Affiliations

¹ Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle, WA, USA.
² Department of Pediatrics, Seattle Children's Research Institute, University of Washington, Seattle, WA 98121, USA. Electronic address: bonnie.ramsey@seattlechildrens.org.

PMID: 25466347
DOI: 10.1016/S2213-2600(14)70272-3

No abstract available

MeSH terms

Aminophenols / therapeutic use
Aminopyridines / therapeutic use
Animals
Benzodioxoles / therapeutic use
Clinical Trials, Phase III as Topic
Cystic Fibrosis / genetics
Cystic Fibrosis / physiopathology
Cystic Fibrosis / therapy*
Cystic Fibrosis Transmembrane Conductance Regulator / drug effects
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis Transmembrane Conductance Regulator / physiology
Disease Models, Animal
Forced Expiratory Volume / physiology
Humans
Mutation / genetics
Quinolones / therapeutic use

Substances

Aminophenols
Aminopyridines
Benzodioxoles
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
lumacaftor